Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Renal Cancer Trends in Molecularly Targeted Therapies

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6554-3

Definition

Today, the oncologist is armed with a multitude of active agents for the therapy of advanced renal cell carcinoma (RCC). This stands in sharp contrast to the landscape that existed just several years ago, at which time only interferon-alpha (IFN-alpha) and interleukin-2 (IL-2) were available. Both of these agents yield limited clinical benefit in most cases, with IL-2 offering only a small chance of a durable response. An enhanced understanding of pathways related to RCC tumorigenesis has led to the development of clinically validated targeted therapies. At present, these agents can be broadly divided into two classes, inhibitors of vascular endothelial growth factor (VEGF)-mediated signaling and inhibitors of the mammalian target of rapamycin (mTOR). Through different mechanisms, both classes antagonize angiogenesis – notably, enhanced angiogenesis as a result of mutation in the von Hippel-Lindau tumor suppressor gene(VHL gene) and consequent accumulation of...

Keywords

Vascular Endothelial Growth Factor Renal Cell Carcinoma Arterial Spin Label Advanced Renal Cell Carcinoma Sunitinib Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Escudier B, Eisen T, Stadler WM et al (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134CrossRefPubMedGoogle Scholar
  2. Escudier B, Pluzanska A, Koralewski P et al (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111CrossRefGoogle Scholar
  3. Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280–1289CrossRefGoogle Scholar
  4. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281CrossRefPubMedGoogle Scholar
  5. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084–1096CrossRefPubMedGoogle Scholar
  6. Klapper JA, Downey SG, Smith FO et al (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer 113:293–301CrossRefPubMedPubMedCentralGoogle Scholar
  7. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608CrossRefPubMedGoogle Scholar
  8. Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428CrossRefPubMedPubMedCentralGoogle Scholar
  9. Xin H, Zhang C, Herrmann A et al (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69:2506–2513CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Division of Hematology OncologySamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical CenterLos AngelesUSA
  2. 2.Department of Medical Oncology and Experimental TherapeuticsCity of Hope Comprehensive Cancer CenterDuarteUSA